Process for preparing novel RHO-associated protein kinase inhibitors and intermediates therein

Abstract

A method for preparing novel Rho-associated protein kinase inhibitors having the structure of Formula A and intermediates in the preparation method. [Formula 1] TIFF2023539275000059.tif39149

Description

Detailed Description of the Invention

[0001] [Field of the Invention] The present invention relates to a process for preparing novel Rho-associated protein kinase inhibitors and intermediates in the process.

[0002] [Background of the invention] Rho-associated protein kinase (ROCK) is a serine / threonine kinase from the AGC kinase family, and includes two isoforms, ROCK1 and ROCK2. ROCK1 and ROCK2 are differentially expressed and regulated in specific tissues. For example, ROCK1 is ubiquitously expressed at relatively high levels, whereas ROCK2 is preferentially expressed in the heart, brain, and skeletal muscle. ROCK was the first downstream effector of Rho proteins discovered, and its biological function is achieved by phosphorylating downstream effector proteins (e.g., MLC, Lin-11, Isl-1, LIMK, ERM, MARCKS, CRMP-2, etc.). Studies have shown that various diseases (e.g., pulmonary fibrosis, cardiovascular disease, neurological diseases, and cancer) are associated with ROCK-mediated pathways. Thus, ROCK is considered an important target for the development of novel drugs.

[0003] Applicants have discovered that (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone can be used as a potent Rho-associated protein kinase (ROCK) inhibitor (see PCT / CN2018 / 093713, incorporated herein by reference in its entirety), however, suitable methods for preparing this compound on a larger scale have not yet been reported.

[0004] [Summary of the Invention] In one aspect, the present invention provides a compound of formula (I)-c [ka] (In the formula, PG is -CH(OR 5 )R 6 is preferably —CH(OCH2CH3)CH3, Hal 1 is a halogen, for example F, Cl, Br or I, preferably Cl, R a and R a’ In each occurrence, H and C 1-6 alkyl, or R a and R a’ together with the groups to which they are attached form a 5- to 10-membered ring system (the ring system is preferably [ka] ) is formed, R is H and C 1-6 is selected from the group consisting of alkyl, R 1 teeth, [ka] or [ka] and preferably [ka] and R 3 , R 4 , R 7 and R 8 is, in each occurrence, H, halogen, -NR 5 R 6 , -OH, C 1-6 Alkyl and -OR 5 are each independently selected from the group consisting of: R 9 and R 10is, in each occurrence, H, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cyclic hydrocarbyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R 5 and -C 1-6 alkylene-O(P=O)(OH), The above alkylene, alkyl, alkenyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl and aralkyl, at each occurrence, are substituted with halogen, C 1-6 Alkyl and -OR 5 each optionally substituted with one or more substituents independently selected from the group consisting of R 5 and R 6 In each occurrence, H, C 1-6 Alkyl, C 3-10 Cyclic hydrocarbyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl, or R 5 and R 6 together with the atoms to which they are attached form a 3- to 12-membered heterocyclic or heteroaromatic ring, m in each occurrence is independently an integer of 0, 1, 2, or 3; n, in each occurrence, is independently an integer of 0, 1, or 2. 1. A method for preparing a compound of formula (I), comprising: The method includes reacting a compound of formula (I)-a with a compound of formula (I)-b under the catalysis of a catalyst (e.g., a metal catalyst, preferably a palladium catalyst) (preferably in the presence of a base) to obtain a compound of formula (I)-c.

[0005] In another aspect, the present invention provides a compound of formula (I): [ka] (In the formula, R 2 is H and C 1-6 is selected from the group consisting of alkyl, The remaining groups are as defined above. 1. A method for preparing a compound of formula (I), comprising: Step 1: reacting a compound of formula (I)-a with a compound of formula (I)-b under the catalysis of a catalyst (e.g., a metal catalyst, preferably a palladium catalyst) (preferably in the presence of a base) to obtain a compound of formula (I)-c; Step 2: Removal of the PG protecting group in the compound of formula (I)-c to obtain a compound of formula (I), wherein R 2 C 1-6 When R is an alkyl group, 2 and further comprising reacting the compound with a reagent containing:

[0006] In another aspect, the present invention provides intermediates involved in the above processes.

[0007] The method of the present invention has various advantages such as fewer by-products and higher yields of the final product, mild reaction conditions, and shorter reaction times, making it suitable for large-scale synthesis. [Brief explanation of the drawings]

[0008] [Figure 1] 1 is an HPLC chromatogram of the reaction solution in Step 9 of Example 1. [Figure 2] 1 is an HPLC chromatogram of a reaction solution in a comparative example.

[0009] [Detailed Description of the Invention] definition Unless otherwise defined in the context, all technical and scientific terms used herein are intended to have the same meaning as commonly understood by those skilled in the art. Reference to technology used herein is intended to refer to the technology commonly understood in the art, including the modifications of those technologies or equivalent replacements that would be obvious to those skilled in the art. Although the following terms are believed to be easily understood by those skilled in the art, the following definitions are nevertheless provided to better explain the present invention.

[0010] The terms "contain," "include," "comprise," "have," or "relate to," and other variations as used herein, are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0011] As used herein, the term "alkylene" refers to a saturated divalent hydrocarbyl, preferably having 1, 2, 3, 4, 5, or 6 carbon atoms, such as methylene, ethylene, propylene, or butylene.

[0012] As used herein, the term "alkyl" is defined as a straight or branched chain saturated aliphatic hydrocarbon. In some embodiments, alkyl has 1 to 12, e.g., 1 to 6, carbon atoms. For example, as used herein, "C 1-6 The term "alkyl" refers to a straight or branched chain group having 1 to 6 carbon atoms (such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl), which is optionally substituted with one or more (e.g., 1 to 3) suitable substituents such as a halogen (in which case the group may be referred to as a "haloalkyl") (e.g., CH2F, CHF2, CF3, CCl3, C2F5, C2Cl5, CH2CF3, CH2Cl, or -CH2CH2CF3, etc.). 1-4The term "alkyl" refers to a straight or branched aliphatic hydrocarbon chain having 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl).

[0013] As used herein, the term "alkenyl" refers to a straight or branched chain monovalent hydrocarbyl having a double bond and 2 to 6 carbon atoms ("C 2-6 Alkenyl refers to "alkenyl" (e.g., vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, and 4-methyl-3-pentenyl. When the compounds of the present invention contain an alkenylene group, the compounds may exist as the pure E (entegene) form, the pure Z (tsammen) form, or any mixture thereof.

[0014] As used herein, the term "alkynyl" refers to a monovalent hydrocarbyl containing one or more triple bonds and preferably having 2, 3, 4, 5 or 6 carbon atoms, such as ethynyl or propynyl.

[0015] As used herein, the term "cycloalkyl" refers to a saturated monocyclic or polycyclic (e.g., bicyclic) hydrocarbon ring (e.g., monocyclic, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or cyclononyl, or bicyclic rings containing spiro, fused, or bridged ring systems (e.g., bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, or bicyclo[5.2.0]nonyl, or decahydronaphthalene, etc.)), which is optionally substituted with one or more (e.g., 1 to 3) suitable substituents. A cycloalkyl has 3 to 15 carbon atoms. For example, "C 3-6The term "cycloalkyl" refers to a saturated monocyclic or polycyclic (e.g., bicyclic) hydrocarbon ring having 3 to 6 ring-forming carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), which is optionally substituted with one or more (e.g., 1 to 3) suitable substituents, such as methyl-substituted cyclopropyl.

[0016] As used herein, the terms "cyclic hydrocarbylene," "cyclic hydrocarbyl," and "hydrocarbon ring" refer to saturated (i.e., "cycloalkylene" and "cycloalkyl") or unsaturated (i.e., having one or more double and / or triple bonds in the ring) monocyclic or polycyclic hydrocarbon rings, for example, having 3 to 10 (preferably 3 to 8, more preferably 3 to 6) ring carbon atoms, including, but not limited to, cyclopropyl(ene)(ring), cyclobutyl(ene)(ring), cyclopentyl(ene)(ring), cyclohexyl(ene)(ring), cycloheptyl(ene)(ring), cyclooctyl(ene)(ring), cyclononyl(ene)(ring), cyclohexenyl(ene)(ring), and the like.

[0017] As used herein, the terms "heterocyclyl," "heterocyclylene," and "heterocycle" refer to saturated (i.e., heterocycloalkyl) or partially unsaturated (i.e., having one or more double and / or triple bonds in the ring) cyclic groups having, for example, 3 to 10 (preferably 3 to 8, more preferably 3 to 6) ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of N, O, and S, and the remaining ring atoms are C. For example, the "3- to 10-membered heterocyclyl(ene)" of a "3- to 10-membered heterocycle" refers to a saturated or partially unsaturated heterocyclyl(ene) or heterocycle having 2 to 9 (e.g., 2, 3, 4, 5, 6, 7, 8, or 9) ring carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms independently selected from the group consisting of N, O, and S. Examples of heterocyclylene, heterocyclyl, and heterocycle include, but are not limited to, oxiranyl(ene), aziridinyl(ene), azetidinyl(ene), oxetanyl(ene), tetrahydrofuranyl(ene), dioxolinyl(ene), pyrrolidinyl(ene), pyrrolidonyl(ene), imidazolidinyl(ene), pyrazolidinyl(ene), pyrrolinyl(ene), tetrahydropyranyl(ene), piperidinyl(ene), morpholinyl(ene), dithianyl(ene), thiomorpholinyl(ene), piperazinyl(ene), or trithianyl(ene). The groups also encompass bicyclic ring systems, including spiro, fused, or bridged systems (e.g., 8-azaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 2-azabicyclo[2.2.2]octane, and the like). The heterocyclylene, heterocyclyl, and heterocycle may be optionally substituted with one or more (eg, 1, 2, 3, or 4) suitable substituents.

[0018] As used herein, the terms "aryl(ene)" and "aromatic ring" refer to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated π-electron system. For example, as used herein, "C 6-10 Aryl(ene)" and "C 6-10The term "aromatic ring" refers to an aromatic group containing 6 to 10 carbon atoms, such as a phenyl(ene) (benzene ring) or a naphthyl(ene) (naphthalene ring). The aryl(ene) or aromatic ring may contain one or more (such as 1 to 3) suitable substituents (e.g., halogen, -OH, -CN, -NO, and C). 1-6 and optionally substituted with alkyl.

[0019] As used herein, the terms "heteroaryl(ene)" and "heteroaromatic ring" refer to monocyclic, bicyclic, or tricyclic aromatic ring systems having 5, 6, 8, 9, 10, 11, 12, 13, or 14 ring atoms, particularly 1, 2, 3, 4, 5, 6, 9, or 10 carbon atoms, and containing at least one heteroatom (e.g., O, N, or S), which may be the same or different. Furthermore, in any case, they may be benzo-fused. In particular, the "heteroaryl(ene)" or "heteroaromatic ring" is selected from the group consisting of thienyl(ene), furyl(ene), pyrrolyl(ene), oxazolyl(ene), thiazolyl(ene), imidazolyl(ene), pyrazolyl(ene), isoxazolyl(ene), isothiazolyl(ene), oxadiazolyl(ene), triazolyl(ene), thiadiazolyl(ene), etc., and benzo derivatives thereof, or pyridinyl(ene), pyridazinyl(ene), pyrimidinyl(ene), pyrazinyl(ene), triazinyl(ene), etc., and benzo derivatives thereof.

[0020] As used herein, the term "aralkyl" preferably refers to an aryl- or heteroaryl-substituted alkyl, where aryl, heteroaryl, and alkyl are as defined herein. Typically, an aryl group can have 6 to 14 carbon atoms, a heteroaryl group can have 5 to 14 ring atoms, and an alkyl group can have 1 to 6 carbon atoms. Exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, phenylpropyl, and phenylbutyl.

[0021] As used herein, the term "halo" or "halogen" is defined to include F, Cl, Br, or I.

[0022] As used herein, the term "nitrogen-containing heterocycle" refers to a saturated or unsaturated monocyclic or bicyclic group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 carbon atoms and at least one nitrogen atom in the ring, which may optionally further include one or more (e.g., 1, 2, 3, or 4) ring members selected from the group consisting of N, O, C=O, S, S=O, and S(=O)2. The nitrogen-containing heterocycle is bonded to the rest of the molecule through the nitrogen atom in the nitrogen-containing heterocycle and any other ring atoms. The nitrogen-containing heterocycle is optionally fused, and preferably bonded to the rest of the molecule through the nitrogen atom in the nitrogen-containing heterocycle and any carbon atom in the fused benzene ring.

[0023] The term "substituted" means that one or more (e.g., 1, 2, 3, or 4) hydrogens on a specified atom are replaced with a selection from the indicated group, provided that the replacement does not exceed the normal valence of the specified atom under the existing circumstances and that the substitution results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0024] When a substituent is described as being "optionally substituted," the substituent may be (1) unsubstituted or (2) substituted. When a carbon of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the carbon (if present) may be replaced separately and / or together with independently selected optional substituents. When a nitrogen of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the nitrogen (if present) may each be replaced with an independently selected optional substituent.

[0025] When substituents are described as being "independently selected" from a group, each substituent is selected independently of the others. Thus, each substituent can be the same or different from the other substituents.

[0026] As used herein, the term "one or more" means a reasonable one or more (eg, 2, 3, 4, 5, or 10).

[0027] As used herein, unless specified, the point of attachment of a substituent may be from any suitable position on the substituent.

[0028] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any of the substitutable ring-forming atoms in that ring.

[0029] The present invention also includes all isotopically labeled compounds identical to those of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominant in nature. Examples of isotopes suitable for inclusion in compounds of the present invention include: 2 H, 3 Isotopes of hydrogen such as H; 11 C. 13 C and 14 carbon, such as C; 36 chlorine, such as Cl; 18 fluorine, such as F; 123 I and 125 iodine, such as I; 13 N and 15 nitrogen such as N; 15 O. 17 O and 18 oxygen such as O; 32 Phosphorus, such as P; and 35 Certain isotopically labeled compounds of the present invention, for example, compounds incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies (e.g., assays). The radioactive isotope tritium, i.e. 3H, and carbon-14, i.e. 14 C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. 11 C. 18 F, 15 O and 13 Substitution with positron-emitting isotopes, such as N, can be useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of the present invention can generally be prepared by processes similar to those described in the accompanying schemes and / or examples and preparations, by substituting an appropriate isotopically labeled reagent for the previously used non-labeled reagent. Solvates according to the present invention include those in which the solvent of crystallization may be isotopically substituted, for example, DO, acetone-d6, or DMSO-d6.

[0030] The term "stereoisomer" refers to an isomer having at least one asymmetric center. Compounds having one or more (e.g., 1, 2, 3, or 4) asymmetric centers can give rise to racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers. Certain individual molecules can exist as geometric isomers (cis / trans). Similarly, compounds of the present invention can exist as mixtures of two or more structurally distinct forms in rapid equilibrium (commonly referred to as tautomers). Typical examples of tautomers include keto-enol tautomers, phenol-keto tautomers, nitroso-oxime tautomers, imine-enamine tautomers, and the like. It is understood that all such isomers and mixtures thereof, in any proportion (60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, etc.), are encompassed within the scope of the present invention.

[0031] Chemical bonds in the compounds of the present invention are represented herein by solid lines ( [ka] ), solid wedge ( [ka] ), or a dotted wedge ( [ka] ) can be used to denote the bond to an asymmetric carbon atom. The use of a solid line to denote a bond to an asymmetric carbon atom is meant to indicate that all possible stereoisomers at that carbon atom (e.g., a specific enantiomer, a racemic mixture, etc.) are included. The use of either a solid line or a dotted wedge to denote a bond to an asymmetric carbon atom is meant to indicate that the depicted stereoisomer is present. When present in a racemic compound, the solid and dotted wedge are used to define relative stereochemistry rather than absolute stereochemistry. Unless otherwise specified, it is intended that the compounds of the present invention may exist as stereoisomers, including optical isomers such as cis and trans isomers, R and S enantiomers, diastereomers, geometric isomers, rotamers, conformational isomers, atropisomers, and mixtures thereof. The compounds of the present invention may exhibit more than one type of isomerism and may consist of mixtures thereof (e.g., racemates and diastereomeric pairs).

[0032] The present invention includes all possible crystalline forms or polymorphs of the compounds of the present invention, either as a single polymorph or as a mixture of two or more polymorphs in any ratio.

[0033] It should also be understood that certain compounds of the present invention do not include derivatives thereof, or can be used in the form of derivatives where appropriate.In the present invention, derivatives include, but are not limited to, salts and solvates.Therefore, the "compounds of the present invention" referred to herein also means to include various derivative forms of the compounds described above.

[0034] Salts of the compounds of the present invention include acid addition salts and base addition salts thereof.

[0035] Suitable acid addition salts are formed from acids which form pharmaceutically acceptable salts, such as acetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, iodine ... These include ionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-naphthylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / hydrogenphosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate, and xinofoate salts.

[0036] Suitable base addition salts are formed from bases which form pharmaceutically acceptable salts, examples of which include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

[0037] For a review of suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, 2002). Methods for preparing salts of compounds of the invention are known to those skilled in the art.

[0038] The compounds of the present invention can exist as solvates (preferably hydrates), which contain polar solvents, particularly water, methanol or ethanol, as structural elements of the crystalline lattice of the compounds. The amount of polar solvent, particularly water, can be present in a stoichiometric or non-stoichiometric ratio.

[0039] The present invention further encompasses the compounds of the present invention that have protecting groups.During any process for preparing the compounds of the present invention, it may be necessary and / or desirable to protect any sensitive or reactive group of the relevant molecule, thereby obtaining the chemically protected form of the compounds of the present invention.This can be achieved by using conventional protecting groups, such as those described in TW Greene & P. ​​G M Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which is incorporated herein by reference.Protective groups can be removed at a later convenient stage using methods known in the art.

[0040] The term "about" refers to a range within ±10%, preferably within ±5%, and more preferably within ±2% of the specified value.

[0041] Preparation method In some embodiments, the present invention provides a method for preparing a compound of formula (I)-c: [ka] (In the formula, PG is -CH(OR 5 )R 6 is preferably —CH(OCH2CH3)CH3, Hal 1 is a halogen, for example F, Cl, Br or I, preferably Cl, R a and R a’ In each occurrence, H and C 1-6 alkyl, or R a and R a’ together with the groups to which they are attached form a 5- to 10-membered ring system (the ring system is preferably [ka] ) is formed, R is H and C 1-6 is selected from the group consisting of alkyl, R 1 teeth, [ka] or [ka] and preferably [ka] and R 3 , R 4 , R 7 and R 8 is, in each occurrence, H, halogen, -NR 5 R 6 , -OH, C 1-6 Alkyl and -OR 5 are each independently selected from the group consisting of: R 9 and R 10 is, in each occurrence, H, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cyclic hydrocarbyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -C(=O)R 5 and -C 1-6 alkylene-O(P=O)(OH), The above alkylene, alkyl, alkenyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl and aralkyl, at each occurrence, are substituted with halogen, C 1-6 Alkyl and -OR 5 each optionally substituted with one or more substituents independently selected from the group consisting of R 5 and R 6 In each occurrence, H, C1-6 Alkyl, C 3-10 Cyclic hydrocarbyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl, or R 5 and R 6 form, together with the atoms to which they are attached, a 3- to 12-membered heterocyclic or heteroaromatic ring (preferably a 5- or 6-membered heterocyclic ring), m in each occurrence is independently an integer of 0, 1, 2, or 3; n, in each occurrence, is independently an integer of 0, 1, or 2. 1. A method for preparing a compound of formula (I), comprising: The method includes reacting a compound of formula (I)-a with a compound of formula (I)-b under the catalysis of a catalyst (e.g., a metal catalyst, preferably a palladium catalyst) (preferably in the presence of a base) to obtain a compound of formula (I)-c.

[0042] In some embodiments, the present invention provides a method for preparing a compound of formula (I): [ka] (In the formula, R 2 is H and C 1-6 is selected from the group consisting of alkyl, The remaining groups are as defined above. 1. A method for preparing a compound of formula (I), comprising: Step 1: reacting a compound of formula (I)-a with a compound of formula (I)-b under the catalysis of a catalyst (e.g., a metal catalyst, preferably a palladium catalyst) (preferably in the presence of a base) to obtain a compound of formula (I)-c; Step 2: Removal of the PG protecting group in the compound of formula (I)-c to obtain a compound of formula (I), wherein R 2 C 1-6 When R is an alkyl group, 2and further comprising reacting the compound with a reagent containing:

[0043] In a preferred embodiment, [ka] teeth, [ka] or [ka] where the groups are attached to the pyrimidine ring at the positions labeled * and to the carbonyl group at the positions labeled **.

[0044] In a preferred embodiment, R is H.

[0045] In a preferred embodiment, R 2 is H.

[0046] In a preferred embodiment, R 5 and R 6 are each independently selected at each occurrence from the group consisting of H, methyl and ethyl, or R 5 and R 6 together with the atoms to which they are attached, [ka] Form.

[0047] In a preferred embodiment, R 3 , R 4 , R 7 and R 8are each independently selected at each occurrence from the group consisting of H, F, Cl, Br, I, —NH 2 , —OH, methyl, trifluoromethyl, —CH 2 -Ph, methoxy, ethoxy, and —CH 2 OCH 3 .

[0048] In a preferred embodiment, R 3 is H.

[0049] In a preferred embodiment, R 4 is selected from the group consisting of H and halogen (eg, F, Cl, Br or I), preferably H or F.

[0050] In a preferred embodiment, R 7 is selected from the group consisting of H and halogen (eg, F, Cl, Br or I), preferably H or F.

[0051] In a preferred embodiment, R 8 is H.

[0052] In a preferred embodiment, R 9 and R 10 is, at each occurrence, H, F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, vinyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, monofluoromethyl, difluoromethyl, trifluoromethyl, acetyl, -CH2CHF2, -CH2OH, -CH2OCH3, -CH2CH2OCH3, -CH2-O(P=O)(OH)2, [ka] , [ka] , [ka] and [ka] are each independently selected from the group consisting of:

[0053] In a preferred embodiment, R 9 In each occurrence, H, C 1-6 Alkyl, C 3-10 Cyclic hydrocarbyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl, and preferably H.

[0054] In a preferred embodiment, R 10 In each occurrence, H and C 1-6 alkyl, preferably H, methyl, ethyl, n-propyl or isopropyl, and most preferably H or methyl.

[0055] In a preferred embodiment, the compound of formula (I)-a has the following structure: [ka] Compound A-51 has the formula: Compounds of formula (I)-b have the following structure: [ka] Compound A-8 has the formula: Compounds of formula (I)-c have the following structure: [ka] Compound A-103 has the formula:

[0056] In a preferred embodiment, the compound of formula (I) is Compound A, which has the following structure: [ka]

[0057] In a preferred embodiment, the palladium catalyst is selected from the group consisting of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, tris(dibenzylideneacetone)dipalladium, triphenylphosphinepalladium and palladium acetate, preferably [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium.

[0058] In a preferred embodiment, the base is an inorganic base selected from the group consisting of potassium acetate, potassium carbonate, cesium carbonate, sodium carbonate, sodium bicarbonate and potassium bicarbonate, preferably potassium acetate or potassium carbonate.

[0059] In a preferred embodiment, in the reaction of the compound of formula (I)-a with the compound of formula (I)-b, the molar ratio of the compound of formula (I)-a to the compound of formula (I)-b is about 1:1 to 1:2, preferably about 1:1 to 1:1.5.

[0060] In a preferred embodiment, in the reaction of the compound of formula (I)-a with the compound of formula (I)-b, the molar ratio of the compound of formula (I)-a to the palladium catalyst is about 200:1 to 80:1, preferably about 150:1 to 90:1.

[0061] In a preferred embodiment, in the reaction of the compound of formula (I)-a with the compound of formula (I)-b, the molar ratio of the compound of formula (I)-a to the base is about 1:1 to 1:5, preferably about 1:1 to 1:3.

[0062] In a preferred embodiment, the reaction of the compound of formula (I)-a with the compound of formula (I)-b is carried out in a mixed solvent of an amide having 1 to 10 carbon atoms (e.g., N,N-dimethylformamide or N,N-dimethylacetamide) and water, and the volume ratio of the amide solvent to water is preferably about 10:1 to 1:1, more preferably about 5:1 to 1:1.

[0063] In a preferred embodiment, the reaction of the compound of formula (I)-a with the compound of formula (I)-b is carried out at a temperature of about 100 to 20°C, preferably about 60 to 50°C.

[0064] In a preferred embodiment, the PG protecting group in the compound of formula (I)-c is removed in the presence of an acid, which is preferably hydrochloric acid.

[0065] In a preferred embodiment, the reaction to remove the PG protecting group in the compound of Formula (I)-c is carried out in an alcoholic solvent having 1 to 10 carbon atoms, including, but not limited to, methanol, ethanol, 1-propanol (n-propanol), 2-propanol (isopropanol), 1-butanol, 2-butanol, and tert-butanol.

[0066] In a preferred embodiment, the reaction for removing the PG protecting group in the compound of formula (I)-c is carried out at a temperature of about 50 to 10°C, preferably about 30 to 20°C.

[0067] In a preferred embodiment, the compound of formula (I)-a can be prepared by the following method: [ka] prepared according to Hal 2 is a halogen, for example F, Cl, Br or I, preferably Cl, The remaining groups are as defined above. 1. A method for preparing a compound of formula (I), comprising: Step A: introducing a PG protecting group into a compound of formula (I)-a-1 to obtain a compound of formula (I)-a-2; Step B: reacting a compound of formula (I)-a-2 under reducing conditions to obtain a compound of formula (I)-a-3, which, if R is not H, further comprises reacting with a reagent containing R; Step C: reacting the compound of formula (I)-a-3 with the compound of formula (I)-a-4 to obtain the compound of formula (I)-a, Preferably, in step A, the compound of formula (I)-a-1 is reacted with ethyl vinyl ether to introduce a protecting group of —CH(OCHCH)CH, and the molar ratio of the compound of formula (I)-a-1 to ethyl vinyl ether is preferably about 1:1 to 1:2, preferably about 1:1 to 1:1.5; Preferably, step A is carried out in an ether solvent (e.g., an ether having 3 to 10 carbon atoms, preferably a cyclic ether, such as furan (including tetrahydrofuran) and dioxane, preferably tetrahydrofuran, 2-methyltetrahydrofuran or 1,4-dioxane), Preferably, step A is carried out in the presence of an acid, which is preferably hydrochloric acid in dioxane; Preferably, step A is carried out at a temperature of about 50-10°C, preferably about 30-20°C; Preferably, the reducing agent used in Step B is sodium sulfide, and the molar ratio of the compound of Formula (I)-a-2 to sodium sulfide is about 1:1 to 1:5, preferably about 1:1 to 1:3; Preferably, the reaction solvent in Step B is an alcoholic solvent having 1 to 10 carbon atoms (including, but not limited to, methanol, ethanol, 1-propanol (n-propanol), 2-propanol (isopropanol), 1-butanol, 2-butanol, and tert-butanol), water, or a mixture of an alcoholic solvent and water; Preferably, step B is carried out at a temperature of about 100-20°C, preferably about 80-70°C; Preferably, the molar ratio of the compound of formula (I)-a-3 to the compound of formula (I)-a-4 in step C is about 1:1 to 1:2, preferably about 1:1 to 1:1.5; Preferably, step C is carried out in the presence of a base, which is preferably an organic base selected from imidazole, triethylamine, pyridine, 2,6-lutidine, DBU, and DIEA, most preferably DIEA, and the molar ratio of the compound (I)-a-3 to the base is preferably about 1:1 to 1:5, preferably about 1:1 to 1:2; Preferably, step C is carried out in an alcoholic solvent having 1 to 10 carbon atoms, including, but not limited to, methanol, ethanol, 1-propanol (n-propanol), 2-propanol (isopropanol), 1-butanol, 2-butanol, and tert-butanol; Preferably, step C is carried out at a temperature of about 120-20°C, preferably about 80-70°C.

[0068] In a preferred embodiment, the compound of formula (I)-a-1 is compound A-2, which has the following structure: [ka] .

[0069] In a preferred embodiment, the compound of formula (I)-a-2 is compound A-21, which has the following structure: [ka] .

[0070] In a preferred embodiment, the compound of formula (I)-a-3 is compound A-31, which has the following structure: [ka] In a preferred embodiment, the compound of formula (I)-b can be prepared by the following method: [ka] prepared according to Hal 3 is a halogen, for example F, Cl, Br or I, preferably Cl, LG is a leaving group such as —OH or a halogen selected from F, Cl, Br and I; The remaining groups are as defined above. 1. A method for preparing a compound of formula (I), comprising: Step I: The compound of formula (I)-b-1 is reacted with R 1 reacting with a reagent containing a group to obtain a compound of formula (I)-b-2; Step II: R 10 is H, step II is not required, 10 reacting with a reagent containing a group to obtain a compound of formula (I)-b-3; Step III: reacting the compound of formula (I)-b-3 with boronic acid or a boric acid ester under the catalysis of a catalyst (e.g., a metal catalyst, preferably a palladium catalyst) (preferably in the presence of a base) to obtain a compound of formula (I)-b; Preferably, R 1 The reagent containing the group [ka] or its hydrochloride salt, Preferably, in Step I, the compound of formula (I)-b-1 and R 1 the molar ratio of the hydroxyl group-containing reagent to the hydroxyl group-containing reagent is about 1:1 to 1:2, preferably about 1:1 to 1:1.5, Preferably, step I is carried out in the presence of a carboxylic acid activating reagent (preferably CDI), and the molar ratio of the compound of formula (I)-b-1 to the carboxylic acid activating reagent is preferably about 1:1 to 1:2, preferably about 1:1 to 1:1.5; Preferably, step I is carried out in an amide solvent having 1 to 10 carbon atoms (e.g., N,N-dimethylformamide or N,N-dimethylacetamide); Preferably, step I is carried out at a temperature between -10°C and 60°C, preferably between 10°C and 30°C; Preferably, in step II, compound-b-2 of formula (I) and R 10 The molar ratio of the hydroxyl group-containing reagent to the hydroxyl group-containing reagent is about 1:1 to 1:15, preferably about 1:1 to 1:10. Preferably, R 10 C 1-6 When R is an alkyl group, 10 the group-containing reagent is an alkylating agent, the alkylating agent is preferably dimethyl carbonate; Preferably, step II is carried out in an amide solvent having 1 to 10 carbon atoms (e.g., N,N-dimethylformamide or N,N-dimethylacetamide); Preferably, step II is carried out in the presence of a base, and the base is preferably an organic base selected from TMED, imidazole, triethylamine, pyridine, 2,6-lutidine, DBU, and DIEA, and most preferably TMED, and the molar ratio of formula (I)-b-2 to the base is preferably about 5:1 to 1:1, preferably about 2:1 to 1:1; Preferably, step II is carried out at a temperature of about 150-80°C, preferably about 130-100°C; Preferably, the palladium catalyst in step III is selected from the group consisting of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, tris(dibenzylideneacetone)dipalladium, triphenylphosphinepalladium and palladium acetate, preferably [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium; Preferably, the base is an inorganic base selected from the group consisting of potassium acetate, potassium carbonate, cesium carbonate, sodium carbonate, sodium bicarbonate and potassium bicarbonate, preferably potassium acetate or potassium carbonate; Preferably, the borate ester is bis(pinacolato)diboron; Preferably, in step III, the molar ratio of compound-b-3 of formula (I) to boric acid or boric acid ester is about 1:1 to 1:2, preferably about 1:1 to 1:1.5; Preferably, the molar ratio of the compound-b-3 of formula (I) to the palladium catalyst is about 200:1 to 80:1, preferably about 150:1 to 90:1; Preferably, the molar ratio of compound-b-3 of formula (I) to the base is about 1:1 to 1:5, preferably about 1:1 to 1:3; Preferably, step III is carried out in an ether solvent (e.g., an ether having 3 to 10 carbon atoms, preferably a cyclic ether, such as furan (including tetrahydrofuran) and dioxane, preferably tetrahydrofuran, 2-methyltetrahydrofuran or 1,4-dioxane); Preferably, step III is carried out at a temperature of about 110-20°C, preferably about 90-70°C.

[0071] In a preferred embodiment, the compound of formula (I)-b-1 is compound A-SM3, which has the following structure: [ka] .

[0072] In a preferred embodiment, the compound of formula (I)-b-2 is compound A-6, which has the following structure: [ka] .

[0073] In a preferred embodiment, the compound of formula (I)-b-3 is compound A-7, which has the following structure: [ka]

[0074] The present invention encompasses any combination of the above embodiments.

[0075] Intermediates In some embodiments, the present invention provides a compound, or a salt, stereoisomer, polymorph, solvate, or isotopically labeled compound thereof, wherein the compound has the structure of Formula (I)-c: [ka] (wherein each group is as defined above). and The compound preferably has the following structure: [ka] Compound A-103 has the formula: [Example]

[0076] The present invention is further described with reference to the following examples, which are not intended to limit the scope of the invention.

[0077] The structure of the compound was confirmed by nuclear magnetic resonance spectroscopy ( 1 The results were confirmed by 1 H NMR or mass spectrometry (MS).

[0078] Chemical shifts (δ) are expressed in parts per million (ppm). 1 H NMR was recorded on a Bruker BioSpin GmbH 400 spectrometer, the test solvents were deuterated methanol (CD3OD), deuterated chloroform (CDCl3) or hexadeuterated dimethyl sulfoxide (DMSO-d6), and the internal standard was tetramethylsilane (TMS).

[0079] Thin-layer chromatography (TLC) was performed on Huanghai HSGF 254 (5 × 20 cm) silica gel plates, and preparative thin-layer chromatography was performed on GF254 (0.4–0.5 nm) silica gel plates manufactured by Yantai.

[0080] The reaction was monitored by thin-layer chromatography (TLC), and the developing solvent systems included dichloromethane and methanol, hexane and ethyl acetate, and petroleum ether and ethyl acetate, adjusted according to the polarity of the compounds to be separated (by adjusting the volume ratio of the solvents or by adding triethylamine, etc.).

[0081] Unless otherwise indicated, starting materials and reagents used in the examples were either commercially available or obtained according to the methods disclosed in WO 2019 / 001572, which is incorporated herein by reference.

[0082] The abbreviations used in this invention have the following meanings: [Table 1]

[0083] Example 1. [ka]

[0084] Step 1: Preparation of (E)-N-(3-(dimethylamino)-2-(4-nitrophenyl)allylidene)-N-methylmethanaminium tetrafluoroborate (A-11) DMF (400 ml) was added to the reaction flask and cooled to 0-10°C. POCl3 (203.0 g, 1.32 mol) was added dropwise to the reaction flask. After the addition was complete, 2-(4-nitrophenyl)acetic acid (A-SM1) (80.0 g, 0.44 mol) was added to the reaction flask. After the addition, the reaction solution was warmed to 80°C and allowed to proceed at this temperature. After TLC showed that the starting material had undergone complete reaction, the reaction solution was cooled to 20-30°C. Ice water (800 ml) was added dropwise to the reaction solution, followed by the dropwise addition of a solution of NaBF4 (72.7 g, 0.66 mol) in water (160 ml). A solid precipitated. The reaction system was cooled to 0-10°C and stirred for 1 hour. The reaction solution was filtered, the filter cake was rinsed with water (160 ml), and the collected filter cake was dried in vacuo at 25±5° C. to give 135.0 g of a yellow solid with a purity of 100% and a yield of 91.2%. MS m / z(ESI): 248.29M + 1 H NMR(400 MHz,DMSO-d6): δ 8.26(d,J=8.7 Hz,2H),7.79(s,2H),7.60(d,J=8.7 Hz,2H),3.28(s,6H),2.47(s,6H).

[0085] Step 2: Preparation of 4-(4-nitrophenyl)-1H-pyrazole (A-2) Ethanol (670 ml), A-11 (134.0 g, 0.40 mol), and acetic acid (20 ml) were added to a reaction flask. After the addition, the reaction temperature was raised to 70-80°C, and 55% hydrazine hydrate (43.7 g, 0.48 mol) was added dropwise to the reaction system. After the addition, the reaction was allowed to proceed at this temperature. After TLC showed that the starting material had completely reacted, the reaction was stopped and cooled to 45±5°C. Water (1340 ml) was added dropwise to the reaction system. After the addition, the reaction was cooled to 0-10°C, stirred for 1 hour, and filtered. The filter cake was rinsed with water (268 ml), collected, and dried under vacuum at 45±5°C to give 74.0 g of a yellow solid, purity: 99.07%, yield: approximately 97.8%. MS m / z(ESI): 190.12 [M+H] + 1H NMR (400 MHz, DMSO-d6): δ 13.20(s,1H),8.29(s,2H),8.20(d,J=8.8 Hz,2H),7.88(d,J=8.8 Hz,2H).

[0086] Step 3: Preparation of 1-(1-ethoxyethyl)-4-(4-nitrophenyl)-1H-pyrazole (A-21) THF (365 ml), A-2 (73.0 g, 0.38 mol), and a 4 M solution of HCl in 1,4-dioxane (2.4 ml, 9.6 mmol) were added to a reaction flask. After the addition, ethyl vinyl ether (41.9 g, 0.579 mol) was added dropwise at 25 ± 5 °C. After the addition, the reaction was stirred. After TLC showed that the starting material had undergone complete reaction, sodium bicarbonate (1.3 g, 15.4 mmol) was added to the reaction and stirred for 1 hour. Water (365 ml) and ethyl acetate (365 ml) were added, and the organic phase was separated and collected and washed once with water (365 ml). The organic phase was collected, concentrated to approximately 150 ml, and n-heptane (365 ml) was added, causing a large amount of solid to precipitate. The mixture was cooled to 0-10 °C, stirred for 1 hour, and filtered. The filter cake was rinsed with n-heptane (150 ml), collected and dried under vacuum at 45±5° C. to give 89.5 g of a light brown solid, purity: 99.1%, yield: about 88.7%. MS m / z(ESI):262.08[M+H] + , 190.20[M-72] + 1 H NMR(400 MHz,DMSO-d6):δ 8.65(s,1H),8.25-8.20(m,2H),8.14(s,1H),7.95-7.89(m,2H),5.58(q,J=6.0 Hz,1H),3.52-3.41(m,1H),3.31-3.23(m,1H),1.64(d,J=6.0 Hz,3H),1.06(t,J=7.04 Hz,3H).

[0087] Step 4: Preparation of 4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)aniline (A-31) Ethanol (264 ml) and A-21 (88.0 g, 0.34 mol) were added to a reaction flask and heated to 70-80 °C. A solution of Na2S·9H2O (222.5 g, 0.93 mol) in water (880 ml) was added dropwise to the reaction flask. After the dropwise addition, the reaction was allowed to proceed at this temperature. After TLC showed that the starting material had completely reacted, the reaction solution was cooled to 40-50 °C and concentrated to remove the ethanol. 2-Methyltetrahydrofuran (352 ml) was added to the reaction mixture. The organic phase was separated and collected, washed with a saturated solution of NaCl (440 ml), concentrated to approximately 220 ml, and cooled to 0-10 °C, whereupon a large amount of solid precipitated. n-Heptane (440 ml) was added dropwise to the reaction mixture, and the temperature was then maintained at 0-10 °C. The mixture was stirred for 1 hour, filtered, the filter cake was rinsed with n-heptane (176 ml), and the solid was collected and dried under vacuum at 40-50° C. to give 73.6 g of a yellow solid, purity: 99.2%, yield: about 94.4%. MS m / z(ESI):232.29[M+H] + 1 H NMR(400 MHz,DMSO-d6):δ 8.08(s,1H),7.72(s,1H),7.29-7.23(m,2H),6.59-6.53(m,2H),5.49(q,J=6.0 Hz,1H),5.01(s,2H),3.46-3.37(m,1H),3.26-3.17(m,1H),1.60(d,J=6.0 Hz,3H),1.03(t,J=7.0 Hz,3H).

[0088] Step 5: Preparation of 2-chloro-N-(4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)phenyl)pyrimidin-4-amine (A-51) A-31 (70.0 g, 0.30 mol), ethanol (350 ml), 2,4-dichloropyrimidine (49.6 g, 0.33 mol), and DIEA (78.2 g, 0.60 mol) were added to the reaction vessel. After the addition, the reaction solution was heated to 75±5°C and stirred at this temperature overnight. After TLC showed that the starting material had completely reacted, the reaction solution was cooled to 45±5°C and concentrated until no distillate was produced. Ethyl acetate (350 ml) and water (350 ml) were added to the system, and the organic phase was separated, collected, and washed with saturated sodium chloride solution (350 ml). The organic phase was collected, concentrated to about 210 ml at 45±5° C., added with methyl tert-butyl ether (350 ml), concentrated to about 210 ml, added with methyl tert-butyl ether (700 ml), heated to 50±5° C., stirred for 1 hour, cooled to 5±5° C., stirred for 1 hour, and filtered. The filter cake was rinsed with methyl tert-butyl ether (140 ml), collected, and dried under vacuum at 45±5° C. to give 93.3 g of a yellow solid, purity: 99.4%, yield: about 91.6%. MS m / z(ESI): 344.29 [M+H] + 1 H NMR(400 MHz,DMSO-d6):δ 10.02(s,1H),8.32(s,1H),8.15(d,J=5.88 Hz,1H),7.91(s,1H),7.66-7.56(m,4H),6.75(d,J=5.88 Hz,1H),5.54(q,J=5.96 Hz,1H),3.50-3.39(m,1H),3.30-3.20(m,1H),1.63(d,J=6.0 Hz,3H),1.05(t,J=7.04 Hz,3H).

[0089] Step 6: Preparation of (6-bromo-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (A-6) 6-Bromo-1H-indole-2-carboxylic acid (80.0 g, 0.33 mol) and DMF (560 ml) were added to a reaction flask, followed by CDI (64.5 g, 0.40 mol), and the reaction was stirred at 25-30 °C. After TLC showed complete conversion of the starting material to the intermediate, 3,3-difluoroazetidine hydrochloride (47.5 g, 0.36 mol) was added to the reaction. After TLC showed complete conversion of the starting material, the reaction was quenched by adding water (1120 ml), stirring for 0.5 hours, and filtering. The filter cake was rinsed with water (160 ml), collected, and dried at 40-50 °C to give 99.5 g of an off-white solid, purity 99.0%, yield: approximately 94.7%. MS m / z(ESI): 315.24 [M+H] + 1 H NMR (400 MHz, DMSO-d6): δ 11.80(s,1H),7.60(m,2H),7.19(m,1H),6.94(m,1H),4.73(brs,4H).

[0090] Step 7: Preparation of (6-bromo-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (A-7) A-6 (98.0 g, 0.31 mol), dimethyl carbonate (224.0 g, 2.49 mol), DMF (490 ml), and TMED (18.0 g, 0.15 mol) were added to the reaction vessel. After the addition, the reaction solution was heated to 110°C and stirred. After TLC showed that the starting material had completely reacted, the reaction was stopped, cooled to 55±5°C, and concentrated under reduced pressure until no more distillate was produced. The reaction solution was cooled to 25±5°C, and water (980 ml) was added. The mixture was then cooled to 0-10°C, stirred for 1 hour, and filtered. The filter cake was rinsed with water (198 ml), collected, and dried under vacuum at 45±5°C to give 96.2 g of a tan solid, purity: 91.0%, yield: approximately 94.0%. MS m / z(ESI): 329.27 [M+H] + 1H NMR (400 MHz, DMSO-d6): δ 7.84(s,1H),7.58(d,J=8.4 Hz,1H),7.24(dd,J=8.4 Hz,1.7 Hz,1H),7.02(s,1H),3.92(s,3H),4.67(brs,4H).

[0091] Step 8: Preparation of (3,3-difluoroazetidin-1-yl)(1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-2-yl)methanone (A-8) A-7 (95.0 g, 0.29 mol), KOAc (70.8 g, 0.72 mol), bis(pinacolato)diboron (80.6 g, 0.32 mol), and 1,4-dioxane (950 ml) were added to the reaction vessel. After the addition, nitrogen flushing was performed three times, and Pd(dppf)Cl2 (2.1 g, 2.9 mmol) was added. After the addition, the reaction solution was heated to 80 °C and allowed to proceed. After TLC showed that the starting material had undergone complete reaction, the reaction was stopped, cooled to 25 ± 5 °C, and filtered. The filter cake was washed with ethyl acetate (475 ml), and the filtrate was collected and combined. The filtrate was washed twice with 10% NaCl (475 ml × 2). The organic phase was collected and concentrated at 45 ± 5 °C until no distillate was produced. Ethyl acetate (143 ml) was added to the mixture and warmed to 50 ± 5°C to obtain a clear solution. n-Heptane (760 ml) was added dropwise to the solution, cooled to 0-10°C, stirred for 1 hour, and filtered. The filter cake was rinsed with n-heptane (190 ml), collected, and dried under vacuum at 45 ± 5°C to obtain 81.5 g of a yellow solid, purity: 98.0%, yield: approximately 75.0%. MS m / z(ESI): 377.22 [M+H] + 1 H NMR (400 MHz, DMSO-d6): δ 7.82(s,1H),7.62(d,J=8 Hz,1H),7.41(d,J=8 Hz,1H),7.01(s,1H),4.75(brs,4H),3.91(s,3H),1.32(s,12H).

[0092] Step 9: Preparation of (3,3-difluoroazetidin-1-yl)(6-(4-((4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)methanone (A-103) A-51 (60.0 g, 0.17 mol), A-8 (72.3 g, 0.19 mol), potassium carbonate (72.4 g, 0.52 mol), DMF (300 ml), and water (60 ml) were added to a reaction flask. After six nitrogen flushes, Pd(dppf)Cl2 (1.28 g, 1.74 mmol) was added. After the addition, the reaction solution was warmed to 55 ± 5 °C and stirred. After TLC showed that the starting material had undergone complete reaction, the reaction solution was collected for HPLC analysis. The HPLC chromatogram is shown in Figure 1, and the retention times and peak area percentages of the starting material and product are shown in the table below: [Table 2] Ethyl acetate (600 ml) and water (600 ml) were added to the reaction solution, and the mixture was allowed to stand at 60±5°C to allow for phase separation. After the organic phase was collected, water (300 ml) was added to the reaction solution. At a temperature of 60±5°C, the aqueous phase was separated, and the organic phase was collected and concentrated under reduced pressure to approximately 300 ml at 45±5°C. Ethyl acetate (300 ml) was added to the mixture, and the mixture was heated to 60±5°C to dissolve the solid. n-heptane (600 ml) was added to the solution, which was cooled to 5±5°C, stirred for 1 hour, and filtered. The filter cake was washed with n-heptane (120 ml), collected, and dried under vacuum at 45±5°C to give 71.2 g of a yellow solid, purity: 98.0%, yield: approximately 73.0%. MS m / z(ESI):558.23[M+H] + 1H NMR(400 MHz,DMSO-d6):δ 9.10(s,1H),8.58(s,1H),8.43(d,J=5.4 Hz,1H),8.37(s,1H),8.22(dd,J=8.4 Hz,1.4 Hz,1H),7.96(s,1H),7.85(d,J=8.2 Hz,2H),7.76(d,J=8.4 Hz,1H),7.69(d,J=8.3 Hz,2H),7.09(s,1H),6.74(d,J=5.8 Hz,1H),5.58(q,J=6.04 Hz,1H),4.77(brs,4H),4.07(s,3H),3.53-3.44(m,1H),3.32-3.25(m,1H),1.67(d,J=6.04 Hz,3H),1.09(t,J=7.0 Hz,3H).

[0093] Step 10: Preparation of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (A) A reaction flask was charged with ethanol (600 ml) and A-103 (60.0 g, 0.11 mol). Concentrated hydrochloric acid (33.6 g, 0.32 mol) was added dropwise at 20-30°C and stirred. After TLC showed that the starting material had completely reacted, triethylamine (43.4 g, 0.43 mol) was added to the reaction mixture and stirred for 1 hour. Water (600 ml) was added to the reaction mixture, which was cooled to 0-10°C, stirred for 1 hour, and filtered. The filter cake was rinsed with water (120 ml), collected, and dried under vacuum at 40-50°C to give 47.2 g of a yellow solid, yield: 90.3%. MS m / z(ESI):486.23[M+H] + 1H NMR(400 MHz,DMSO-d6):δ 11.12(s,1H),8.49(s,1H),8.41(d,J=6.9 Hz,1H),8.13(s,2H),7.97(d,J=8.4 Hz,1H),7.89(d,J=8.4 Hz,1H),7.76(m,4H),7.16(s,1H),6.96(d,J=7.2 Hz,1H),4.90(s,2H),4.56(s,2H),4.05(s,3H).

[0094] Comparative Example [ka] A-5 (1.5 g, 4.03 mmol), A-8 (1.67 g, 4.44 mmol), potassium carbonate (1.71 g, 12.3 mmol), DMF (10 ml), and water (2 ml) were added to a reaction flask, and the atmosphere was purged with nitrogen six times. Pd(dppf)Cl2 (30.3 mg, 41.2 μmol) was then added. After the addition, the reaction mixture was heated to 55 ± 5°C and stirred for 22 hours. The reaction mixture was subjected to HPLC analysis. The HPLC chromatogram is shown in Figure 2, and the retention time and peak area of ​​the main peak are shown in the table below. [Table 3]

[0095] HPLC analysis showed that starting material A-5 underwent complete reaction, but the reaction products were very complex. Among them, target product A-111 (retention time: 10.104 min) accounted for only 25.66%, the deprotected product (A-4) of starting material A-5 (retention time: 9.936 min) accounted for 25.96%, starting material A-8 (retention time: 14.492 min) accounted for 16.48%, and compound A (retention time: 9.839 min) accounted for 0.25%.

[0096] In addition to those described herein, various modifications of the present invention will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. Each reference, including all patents, applications, journal articles, books, and any other disclosures mentioned herein, is incorporated herein by reference in its entirety.

Claims

Claim 1: A method for preparing compound A-103, comprising: 【Chemistry 1】 A method comprising reacting compound A-51 with compound A-8 in the presence of a base under the catalysis of a palladium catalyst to obtain compound A-103.

2. A method for preparing compound A, comprising: 【Chemistry 2】 Step 1: reacting compound A-51 with compound A-8 in the presence of a base under the catalysis of a palladium catalyst to obtain compound A-103; Step 2: removing the —CH(OCH 2 CH 3 )CH 3 group in compound A-103 to obtain compound A; A method comprising:

3. 3. The method of claim 1, wherein the palladium catalyst is selected from the group consisting of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, tris(dibenzylideneacetone)dipalladium, triphenylphosphinepalladium, and palladium acetate.

4. The method of claim 3, wherein the palladium catalyst is [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium.

5. 3. The method of claim 1 or 2, wherein the base is an inorganic base selected from the group consisting of potassium acetate, potassium carbonate, cesium carbonate, sodium carbonate, sodium bicarbonate and potassium bicarbonate.

6. The method of claim 5, wherein the base is potassium acetate or potassium carbonate.

7. The method of claim 2, wherein the —CH(OCH 2 CH 3 )CH 3 group in compound A-103 is removed in the presence of an acid.

8. The method of claim 7, wherein the acid is hydrochloric acid.

9. The method according to claim 8, further comprising preparing compound A-51: 【Transformation 3】 The step of preparing compound A-51 comprises: Step A: introducing a —CH(OCH 2 CH 3 )CH 3 group into compound A-2 to obtain compound A-21; Step B: reacting compound A-21 under reducing conditions to obtain compound A-31; Step C: reacting compound A-31 with compound A-SM2 to obtain compound A-51; 3. The method of claim 1 or 2, comprising:

10. The method further comprising preparing compound A-8: 【Chemistry 4】 The step of preparing compound A-8 comprises: Step I: Compound A-SM3 is reacted with 【Transformation 5】 to obtain compound A-6; Step II: reacting compound A-6 with dimethyl carbonate to obtain compound A-7; Step III: reacting compound A-7 with bis(pinacolato)diboron under the catalysis of a catalyst to obtain compound A-8; 3. The method of claim 1 or 2, comprising:

11. The method of claim 10, wherein the catalyst in step III is a metal catalyst.

12. The method of claim 11, wherein the metal catalyst is a palladium catalyst.

13. The method of claim 10, wherein step III is carried out in the presence of a base.

14. The structure: 【Transformation 6】 or a salt, stereoisomer, solvate, or isotopically labeled compound thereof.

Images